Leading the development of the Resiniferatoxin program focusing on value preservation, expanding portfolio indications, strengthening intellectual property, and establishing global merger and acquisition partnerships aimed at investment or joint venture opportunities. Driving strategic planning for the next phases of drug development, including Phase 3 trials for osteoarthritis of the knee, Phase 2 for cancer pain, and Phase 1 for Morton’s Neuroma and Trigeminal Neuralgia. Overseeing post-reacquisition value creation strategies and assessing the feasibility of spinning out the asset as an independent company (Fire Therapeutics).

Providing consulting services to human life sciences and animal health companies, with a focus on guiding human life science organizations in assessing and planning the transition of innovative assets into the animal health sector. Assisting early-stage animal health companies in structuring their operations, preparing investor presentations, driving growth, and maximizing shareholder value.

Executive Leadership Team Member..Head of resiniferatoxin (RTX) human and animal health drug development program.Head of corporate development.BDL and IR functions as required.Special projects (business operations and program execution) as assigned by CEO.As Senior Vice President of Corporate Development and Head of the RTX Business Unit, spearheaded strategic relationships with analysts, private banking, and institutional investors. Directed organizational communication efforts through investor relations, public relations, and diverse marketing channels. As a core member of the executive leadership team, contributed to strategy development, oversaw high-need, high-value drug development initiatives, facilitated go-to-market tactical planning, and fostered key internal and external partnerships. Led the RTX Business Unit, managing all aspects of the drug development program, including establishing strategies for global commercial operations or strategic licensing. Successfully established international vendor relationships, ensured GMP compliance in manufacturing, and developed a complex supply chain for a highly potent toxin extracted from latex. Oversaw team management, including professional development, performance evaluation, policy adherence, and compensation planning. Ensured departments achieved individual and collective goals while maintaining accountability to shareholders and the public. Responsible for securing capital requirements and ensuring the proper execution of financial instruments to support organizational objectives.

Responsible for establishing the company's goals, strategies and execution of long-term vision as set by the board of directors. Provide adequate and timely information to the Board to enable it to effectively execute its oversight role. Oversee budgets and ensures resources are properly allocated. Direct staff, including organizational structure, professional development, motivation, performance evaluation, discipline, compensation, personnel policies, and procedures. Ensure departments meet individual goals. Responsible for overall accountability to shareholders and the general public. Responsible for capital requirement and ensuring proper execution of financial instruments as necessary. Oversight of R&D, business development & licensing pipeline. Responsible for commercial operations including revenue generation and meeting profitability goals. Provide translational support to Sorrento human healthcare programs (de-risking approach through animal health and human healthcare synergies).

VetStem Biopharma (formerly Vet-Stem Inc.) was formed in 2002 to bring regenerative medicine to the veterinary profession. This privately held biotechnology enterprise, based near San Diego (California), offers veterinarians access to autologous adipose derived stem-cell therapy among other regenerative treatment modalities. As President and Chief Commercial Officer, led the establishment and achievement of the company's long-term goals and strategies. Held oversight responsibility for all client-facing and operational functions, including Sales, Marketing, Customer Service, Technical Services, Finance, Human Resources, Laboratory Operations, Clinical Development, and Business Development. Managed full multi-million-dollar P&L responsibilities, driving financial performance and operational excellence. Focused on employee engagement, goal setting, and team development. Maintained overall accountability to shareholders through the board of directors. Successfully executed a full organizational turnaround, conducted due diligence, and concluded a major strategic exit through a high-value M&A deal.

Developed and executed strategic direction for marketing operations, overseeing P&L, budgets, branding, and tactical initiatives across 600 pet healthcare locations in 47 states, supporting 15,000 employees and generating over $1.4B in annual sales. Led a marketing team of 23 full-time staff and managed eight marketing agencies (100+ FTEs) within a tightly integrated network, with an annual marketing budget exceeding $30M and achieving returns of up to 10:1 on key initiatives. Reorganized the department into functional areas, including hiring, training, and promoting employees to build a high-performance team. Selected and collaborated with best-in-class marketing agencies, ensuring alignment with VCA's profile and service requirements across digital, print, and social media channels, all with strict quality control and ROI oversight. Implemented evidence-based marketing principles, incorporating market research and strong data analytics. Re-structured campaign planning, execution, and reporting processes, establishing SOPs and best practices across the organization. Introduced marketing automation and web-based call management systems, generating over $35M in incremental new client business annually with an initial investment of less than $0.5M. Achieved ROI of 6:1 to 10:1 and payback periods of under six months for most initiatives. Consistently optimized marketing expenditures, reducing costs by over 20% over a three-year period.

Led the global re-evaluation, rebranding, and relaunch of the Zubrin® tablets initiative, strategically planning the future positioning of a “quality of life” product range from feasibility through development and market launch. Managed NSAID and chronic care product portfolios, including P&L oversight and brand repositioning in the U.S. Defined clinical safety trials, managed key opinion leader (KOL) relationships, and collaborated with R&D on formulation improvement projects. Negotiated agreements and developed the architecture for launching senior-specific nutraceuticals in European markets. Successfully achieved top positioning for Zubrin® as the ‘uniquely safe animal health NSAID’ in veterinarians’ minds, strengthening brand recognition and market impact.

Senior brand manager, InterceptorPromoted by the Global CEO to lead the Interceptor brand, focusing on strategic planning and sales initiatives for 2004 and 2005. Managed P&L responsibilities, including an $8M advertising and promotions budget, driving brand growth from $97M to $130M. Achieved a record-breaking milestone by capitalizing on the “Proheart6 recall,” capturing three market share points from Heartgard, equivalent to a $9M gain.Senior Brand manager, Ethicon productsLed a business development negotiation project, successfully completing it and subsequently tasked with launching a new business unit. Aligned strategies and effectively leveraged Johnson & Johnson resources to ensure seamless integration. Managed all aspects of the business unit's launch, including marketing, distribution, sales, and training within the organization.Achieved a successful integration and re-launch of the product line in record time, from contract signing in October to market launch in January. Delivered exceptional first-year results, achieving a +35% increase over the best performance of the previous distribution partner (Schering-Plough). Ensured consistent execution of the business unit’s 5-year plan, meeting or exceeding all growth objectives.E-business and Direct marketing manager (brought on board by previous manager)Appointed to the role by a previous manager to lead the re-evaluation, design, development, and implementation of an e-business strategy. Successfully developed and launched direct marketing pilot initiatives, integrating innovative approaches to enhance business performance and customer engagement.

Managed all online and direct marketing initiatives, seamlessly integrating them with offline campaigns to drive retention, acquisition, and support for Petco's direct initiatives. Oversaw an e-marketing budget exceeding $2M, delivering over $6M in profit from direct campaigns in 2002. Achieved exceptional results, exceeding lead generation goals by 240% and new customer acquisition targets by 8%, all while reducing direct marketing spend by 20%.

Co-founder and owner of a pioneering medical health data management company for pet owners and veterinarians. Designed and implemented the business model while overseeing marketing and sales operations in a 12-employee startup. Secured one international patent for an online medical record system for pets. Led two successful rounds of venture capital funding, raising $1M and $3M, with the company reaching an $8M valuation at the time of departure.

Managed "non-core" products, including intra-mammary and oral antibiotics, with a focus on European SKU rationalization, licensing, and special projects. Successfully licensed $2M in new products, doubling the $1M target. Optimized SKUs across Europe, achieving significant cost savings. Revitalized Swiss distribution operations, transforming a 15% annual sales decline into +25% growth in the first year and +30% in the second year.

Diagnostics Business Unit Manager (Tampa, Florida):Established a new diagnostics department in the U.S. division, leading market analysis, USDA product registration, and product launch strategies. Secured regulatory approval for diagnostic imports in just three months (vs. the expected 14 months) and successfully launched three products within two years: AB Check™ (susceptibility test), Sphervet™ reagents (IBR, Rotavirus, Coronavirus), and Ovucheck™ (Progesterone tests).R&D Clinical Trials Manager (Lure, France):Oversaw the management, statistical analysis, and reporting of clinical trials for regulatory registration and post-approval studies. Published findings in a peer-reviewed journal on the long-term efficacy of Tolfedine (NSAID) under extended protocols.